As of 2025-08-13, the EV/EBITDA ratio of C4 Therapeutics Inc (CCCC) is -0.94. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. CCCC's latest enterprise value is 107.77 mil USD. CCCC's TTM EBITDA according to its financial statements is -114.73 mil USD. Dividing these 2 quantities gives us the above CCCC EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 12.1x - 13.8x | 13.2x |
| Forward P/E multiples | 15.0x - 29.4x | 19.7x |
| Fair Price | (23.55) - (21.57) | (25.86) |
| Upside | -1151.2% - -1063.2% | -1254.3% |
| Date | EV/EBITDA |
| 2025-08-12 | -0.97 |
| 2025-08-11 | -1.05 |
| 2025-08-08 | -1.10 |
| 2025-08-07 | -1.15 |
| 2025-08-06 | -0.77 |
| 2025-08-05 | -0.80 |
| 2025-08-04 | -0.85 |
| 2025-08-01 | -0.87 |
| 2025-07-31 | -0.82 |
| 2025-07-30 | -0.89 |
| 2025-07-29 | -0.95 |
| 2025-07-28 | -0.90 |
| 2025-07-25 | -0.95 |
| 2025-07-24 | -0.97 |
| 2025-07-23 | -1.05 |
| 2025-07-22 | -0.93 |
| 2025-07-21 | -0.96 |
| 2025-07-18 | -0.99 |
| 2025-07-17 | -0.90 |
| 2025-07-16 | -0.80 |
| 2025-07-15 | -0.86 |
| 2025-07-14 | -1.03 |
| 2025-07-11 | -0.93 |
| 2025-07-10 | -0.78 |
| 2025-07-09 | -0.80 |
| 2025-07-08 | -0.61 |
| 2025-07-07 | -0.49 |
| 2025-07-03 | -0.47 |
| 2025-07-02 | -0.49 |
| 2025-07-01 | -0.49 |
| 2025-06-30 | -0.44 |
| 2025-06-27 | -0.42 |
| 2025-06-26 | -0.49 |
| 2025-06-25 | -0.51 |
| 2025-06-24 | -0.52 |
| 2025-06-23 | -0.46 |
| 2025-06-20 | -0.43 |
| 2025-06-18 | -0.44 |
| 2025-06-17 | -0.48 |
| 2025-06-16 | -0.56 |
| 2025-06-13 | -0.59 |
| 2025-06-12 | -0.56 |
| 2025-06-11 | -0.49 |
| 2025-06-10 | -0.52 |
| 2025-06-09 | -0.59 |
| 2025-06-06 | -0.62 |
| 2025-06-05 | -0.46 |
| 2025-06-04 | -0.51 |
| 2025-06-03 | -0.47 |
| 2025-06-02 | -0.38 |